CD274 and non-small cell lung carcinoma: Durvalumab, that is available under the brand name Imfinzi, is another unconjugated human IgG1 kappa immunoglobulin against PD-L1 which is currently licensed in the UK for the treatment of non-resectable non-small-cell lung cancer (NSCLC) [39].